



Mountain View Pharmaceuticals, Inc., Announces Receipt of a Qualifying Therapeutic Discovery Project Grant for Research on PEG-Protein Drug Conjugates

MENLO PARK, CA (November 2, 2010) – Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of a grant of more than \$240,000 under the Qualifying Therapeutic Discovery Project (“QTDP”) program for its application titled:

PharmaPEG Technology for PEG-Protein Drug Conjugates.

PharmaPEG[®] is MVP’s registered trademark for a form of poly(ethylene glycol) (“PEG”) that is less antigenic and less immunogenic than conventional methoxyPEG. Leading biotech innovators say that the new Therapeutic Discovery Project, which makes available a tax credit to companies with 250 or fewer employees, will have a positive impact on advancing life-saving therapies and cures for patients, and U.S. biotechnology competitiveness, while helping to sustain and create jobs.

“Support from the Qualifying Therapeutic Discovery Project will enable MVP to accelerate its research on new treatments for cancer, multiple sclerosis, anemia, immunodeficiency and several other debilitating diseases, while preserving and creating new high-wage, high-value jobs,” said Dr. Merry R. Sherman, CEO and President of MVP.”

About the QTDP Tax Credits and Grants

The Qualifying Therapeutic Discovery Project tax credit is a \$1 billion fund established under section 48D of the Internal Revenue Code (IRC), which section was added to the IRC earlier this year by the Patient Protection and Affordable Care Act (P.L. 111-148). The credit is available to companies with 250 or fewer employees and covers up to 50 percent of qualifying investments in projects aimed at creating new therapies, reducing long-term health care costs, or significantly advancing the goal of curing cancer within the next 30 years. To provide an immediate boost to U.S. biomedical research, the credit is available for qualifying investments made or to be made in taxable years beginning in 2009 or 2010 up to a maximum of \$5 million. Companies may also elect to receive the credit as a grant.

About Mountain View Pharmaceuticals, Inc. (MVP)

MVP is a privately-held California corporation with expertise in the application of advanced polymer-coupling technology to make protein-based drugs safer and longer acting. To date, 128 of MVP’s patent applications have been granted in more than 40 countries. Of these patents, 77 are licensed to Savient Pharmaceuticals, Inc., for the right to make, use, offer for sale and sell pegloticase. This drug is a selectively PEGylated enzyme (“uricase”) that degrades uric acid and has been shown to be safe and effective for the treatment of adults with chronic refractory gout. On September 14, 2010, the U.S. Food and Drug Administration approved its sale under the trade name KRYSTEXXA™. MVP expects to earn milestone payments and tiered royalties on sales of KRYSTEXXA in the U.S. and, eventually, in other countries after approval by their regulatory agencies. Further information about MVP and about KRYSTEXXA is available at www.mvpharm.com and at www.krystexxa.com, respectively.